These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 36711204)
1. High clinical diagnostic accuracy of combined salivary gland and myocardial metaiodobenzylguanidine scintigraphy in the diagnosis of Parkinson's disease. Li S; Yue L; Chen S; Wu Z; Zhang J; Hong R; Xie L; Peng K; Wang C; Lin A; Jin L; Guan Q Front Aging Neurosci; 2022; 14():1066331. PubMed ID: 36711204 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of patients with Parkinson's disease with reduced Ebina J; Mizumura S; Morioka H; Shibukawa M; Nagasawa J; Yanagihashi M; Hirayama T; Ishii N; Kobayashi Y; Inaba A; Orimo S; Kano O J Neurol Sci; 2024 Mar; 458():122932. PubMed ID: 38401301 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease. Brandl SJ; Braune S Clin Auton Res; 2019 Dec; 29(6):567-574. PubMed ID: 29869732 [TBL] [Abstract][Full Text] [Related]
11. Combination of midbrain-to-pontine ratio and cardiac MIBG scintigraphy to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. Sakuramoto H; Fujita H; Suzuki K; Matsubara T; Watanabe Y; Hamaguchi M; Hirata K Clin Park Relat Disord; 2020; 2():20-24. PubMed ID: 34316615 [TBL] [Abstract][Full Text] [Related]
12. Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review. Pitton Rissardo J; Fornari Caprara AL Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891838 [TBL] [Abstract][Full Text] [Related]
13. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Orimo S; Suzuki M; Inaba A; Mizusawa H Parkinsonism Relat Disord; 2012 Jun; 18(5):494-500. PubMed ID: 22321865 [TBL] [Abstract][Full Text] [Related]
14. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Treglia G; Cason E; Stefanelli A; Cocciolillo F; Di Giuda D; Fagioli G; Giordano A Clin Auton Res; 2012 Feb; 22(1):43-55. PubMed ID: 21792729 [TBL] [Abstract][Full Text] [Related]
15. Optimal Protocol and Clinical Usefulness of Chun IK Nucl Med Mol Imaging; 2023 Jun; 57(3):145-154. PubMed ID: 37187951 [TBL] [Abstract][Full Text] [Related]
17. Yang T; Wang L; Li Y; Cheng M; Jiao J; Wang Q; Guo H J Neurol Sci; 2017 Feb; 373():48-51. PubMed ID: 28131225 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Treglia G; Stefanelli A; Cason E; Cocciolillo F; Di Giuda D; Giordano A Clin Neurol Neurosurg; 2011 Dec; 113(10):823-9. PubMed ID: 21962800 [TBL] [Abstract][Full Text] [Related]
19. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Shimizu S; Hirao K; Kanetaka H; Namioka N; Hatanaka H; Hirose D; Fukasawa R; Umahara T; Sakurai H; Hanyu H Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):184-192. PubMed ID: 26233438 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes. Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]